Jennifer Doe, MD, MBA, MSc, FACP

WORK EXPERIENCE

Independent Biotech/Pharma 1-2022 to present

- Consultant for private/public biotechs and VC/PE for drug development/strategy in multiple therapeutic areas using several modalities

Precision Oncology 1-2022 to present
Board of Directors

Primevax
Board of Directors 4-2021 to present
Scientific Advisory Board 4-2020 to present

iTeos Therapeutics 8-2023 to 9-2024
Chief Medical Officer (interim/fractional-full time)

- Led initiation of Phase 3 in collaboration with GSK
- Led BoD approval for second late phase trial
- Designed and received BoD approval for biomarker study
- Led development of Phase 2 for ENT-1 and Phase 1 development for undisclosed asset
- Led implementation of decision-making strategy for all programs including discontinuation of asset
- Led overall strategy for all clinical assets including GSK collaboration as JSC member
- Reorganized clinical group consisting of 40-45 reports

Innate Pharma 7-2020 to 9-2023
Chief Medical Officer, Executive Vice President

- Restructured corporate strategy for company which included implementation of processes for decision making and a new development plan for lead proprietary asset (lacutumab) in T-cell lymphomas including helping to build the commercial organization and returning the commercial asset Lumoxiti to AstraZeneca
- Led with CEO earning calls including covering pre-clinical assets (NK-cell Engager) and clinical assets (proprietary and partnered)
- Led with, and without, CEO analyst and investor calls
- Restructured and managed clinical (operations and development), regulatory, safety, biostats/data management, and medical affairs
- Designed and executed trials in oncology, hematology, inflammation, and infectious disease
- Managed team of 20-25 people remotely for this French-based company

Parker Institute of Cancer Immunotherapy 4-2017 to 4-2021
Medical Director and Advisor

- Advised on the execution, strategy, and design of trials and decision for further development
- Completed first trial with Apexigen in 18 months, collaborating with academic institutes, pharmaceutical companies and non-profit organizations in pancreatic cancer and reached decision point for further development
- Designed, implemented, and created go/no-go decisions for platform studies in multiple oncology indications
- Collaborated with several companies to utilize their assets in combinations in oncology
- Assisted and advised CMO in building safety and clinical departments and developing strategies for clinical programs from ground up

Tizona Therapeutics 7-2019 to 7-2020
Chief Medical Officer, Senior Vice President

- Built infrastructure for clinical, regulatory, and safety departments
- Executed and redeveloped clinical strategy for anti-CD39 in collaboration with AbbVie

- Successful initiation of clinical trial for second molecule (anti-HLA-G) and developed clinical strategic plan for Gilead transaction
- Completed Gilead option to acquisition deal (anti HLA-G) and formed separate company (Trishula Therapeutics) for AbbVie collaboration (anti-CD39).

Arcus Biosciences 4-2017 to 6-2019
Vice President, Clinical Development (Head of Clinical, Safety and Regulatory)

- Reported to CEO and made clinical and strategic decisions about assets (small molecules and antibodies)
- Built infrastructure for clinical, safety, and regulatory departments and grew team from 1 person to 20 people
- Planned and executed the clinical strategy for four molecules (small molecules and antibodies)
  - Executed a total of 6 global trials, 4 of which had reached recommended phase 2 dose and developed "go/no-go" criteria for further development
  - Filed 6 successful INDs
  - Executed and reached milestones on time
- Developed clinical publication strategy including first clinical publication for company
- Contributed to company filing for IPO and being listed on the NYSE
- Led the collaboration efforts and decisions for molecules with Gloria Pharmaceuticals (China) and Taiho Pharmaceuticals (Japan)
- Patents Filed
  - Doe, Jennifer, J. 2019. Parenterally administered immune enhancing drugs.
  - Doe, Jennifer. 2019. Dosing with an azolopyrimidine compound.

Medimmune 6-2013 to 4-2017
Director, Clinical Development

- Led and designed clinical trials for 4 immunotherapy assets, ranging from pre-clinical to proof of concept
- Early lung lead for durvalumab and tremelimumab - implemented the design, execution, and decision to take into phase 3 trials
  - Early lung lead in the design of the Mystic trial (Phase 3 trial) in lung cancer
  - Early lung lead for durvalumab (Imfinzi) adjuvant lung cancer trial BLA filing and approval
- Strategic lead for key assets in both solid and hematologic indications including acalabrutinib (Acerta)
- Led the due diligence and collaboration with Innate and Celgene
- Led and initiated first combination studies with durvalumab, tremelimumab, or lenalidomide in MDS and lymphomas and first triplets for MDS with durvalumab, tremelimumab and azacytidine.
- Patents
  - Doe, Jennifer. 2015. Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer.
- Awards
  - Patent of the Year Award - 2016
  - Publication of the Year Award - 2016, 2017
  - Global Excellence Award – 2015

Uniformed Services University of the Health Sciences 2012 to 2018
Associate Professor of Medicine

Walter Reed National Military Medical Center (WRNMMC) 2010 to 2013
Staff Medical Oncologist/Hematologist

- Director, Hematology Team and Leukemia Service
- Member of Lung, Head and Neck and CNS (Central Nervous System) Tumor Team
- Institutional Review Board (IRB) member
- Scientific Review Committee member

.

National Institutes of Health (NIH) National Cancer Institute (NCI) 2008 to 2013
Attending Clinical Staff

- Attending in Multiple Myeloma clinic

Food and Drug Administration 2007 to 2008
Medical Reviewer

National Institutes of Health (NIH) National Cancer Institute (NCI) 2006 to 2008
Oncology Fellowship
Associate Investigator

University of Maryland 2005 to 2006
Hematology/Oncology Fellowship
Assistant Instructor in Medicine

National Institutes of Health (NIH) 2004 to 2005
Research Fellow in Pain
Associate Investigator

National Institutes of Health (NIH) 2003 to 2004
Pain and Palliative Care Fellowship

Overlook Hospital/University of Medicine and Dentistry of New Jersey 2000 to 2003
Residency

- **House Staff President** 2001-2002
- **Chief Resident** 2002-2003

EDUCATION

Kelley School of Business - Indiana University 2023
MBA

University of Maryland
MSc, Pharmacology (earned concurrently during Oncology fellowship) 2007

- Phi Beta Kappa Honor Society

Annamalai University 1999
MBBS (Medicine Bachelor, Bachelor Surgery) (USA MD equivalent)

University of Miami 1993
BS, Microbiology/Immunology + **BA,** Psychology

MEMBERSHIPS

Member, Phi Beta Kappa, 2009-present
Fellow, American College of Physicians, 2009-present
American Association of Physicians of Indian Origin 2009- present
Associate, American Society of Hematology 2005-present
Associate, American Association of Cancer Research 2004- present
Associate, American Society of Clinical Oncology, 2004-present
Member, American Medical Association, 2001-present
Member, Indian Medical Association, 2000-present

PUBLICATION AND PRESENTATIONS

Publications:

Agonistic CD40 Monoclonal Antibody APX005M and Chemotherapy with or without Nivolumab for the Treatment of Metastatic Ductal Pancreatic Adenocarcinoma.

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies.

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.

Reviewing the role of healthy volunteer studies in drug development.

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Safety and anti-tumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Phase II Clinical Trial of Cediranib in Patients with Castration-Resistant Prostate Cancer

Castrate-resistant prostate cancer: the right targets and combinations

"Constipation and Diarrhea" *Handbook of Supportive Oncology*

"Epidemiology and Prognostication in Non-Cancer Diagnoses" *Principles and Practice of Palliative Care and Supportive Oncology*

Multiple Myeloma and Multiple Neoplasia: the Association with Renal Cell Carcinoma

Scleritis complicating zoledronic acid infusion

"Alopecia." *Principles and Practices of Oncology*

Opioid Analgesics: Practical Prescribing Considerations." *Advances in Cancer Pain Management*

Methadone: "Case Series in Dosing"

Wealth from Health: A Model for Incentive-based Disease Management.

Oral Presentations:

Unifying Treatment Algorithms for Immunological Toxicity oral presentation at Rationale Combinations

Safety and efficacy of durvalumab (MEDI4736) plus tremelimumab in advanced non-small-cell lung cancer (NSCLC)

"Phase II trial of Cediranib (AZD 2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)"

"Pain and Palliative Care in the US: An Overview"

"Pulmonary Mucormycosis"

"Babesiosis, Ehrlichiosis and Lyme Coinfection"

Conference Presentations:

Feasibility and Utility of Synthetic Control Arms Derived from Real-World Data to Support Clinical Development.

Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies.

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies.

Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity.

Preliminary results from an ongoing Phase 1 study of AB122, an anti-programmed cell death-1 (PD-1) monoclonal antibody, in patients with advanced solid tumors.

A Phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with breast or gynecologic malignancies.

A Phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with gastrointestinal malignancies.

A Phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with carboplatin/pemetrexed and pembrolizumab in lung cancer patients.

A Phase 1 study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, with AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced malignancies.

Final results of the Phase 1 study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response.

Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors.

AB928, a dual antagonist of the $A_{2a}R$ and $A_{2b}R$ adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy.

A Phase 1 study of MEDI1873 in adult patients with select advanced solid tumors.

Inhibition of pEGFR in paired tumour biopsies from TKI treatment-naïve EGFR mutant NSCLC patients treated with gefitinib (EGFR inhibitor) or gefitinib in combination with durvalumab (anti-PDL1).

Phase 1b study of the safety and antitumor activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC.

Phase 1 study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with advanced solid tumors.

Phase 1b/2 study to evaluate the safety and efficacy of MEDI4736 and tremelimumab (treme), given as monotherapy or in combination, in patients with metastatic or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.

A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC.

Safety and tolerability results from a Phase I study of MEDI4736, a human IgG1 PD-L2 antibody, combined with gefitinib in patients with NSCLC.

Phase 2 study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients with Glioblastoma (GBM).

A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.

Pharmacokinetics and Pharmacodynamics of MEDI4736, a Fully Human Anti- Programmed Death Ligand 1(PD-L1) Monoclonal Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).

Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.

Phase 1b, open-label study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients with advanced NSCLC.

Phase 1, open-label study of MEDI0680, an anti-programmed cell death-1 antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 antibody, in patients with advanced malignancies.

A Phase 1, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC).

A Phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1(PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).

A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.

A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer.

"Phase II trial of Cediranib (AZD 2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)"

"Response evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in a phase II study of cediranib in docetaxel-resistant, castrate resistant prostate cancer (CRPC)"

" A Phase II study of AZD-2171 in docetaxel-resistant, castrate resistant prostate cancer (CRPC)"

"Analgesic Effects of Vanilloid Receptor Inactivation by Capsaicin in the Oral Surgery Model"

" Capsaicin as a Preventive Analgesic in the Oral Surgery Model"

"Farnesylthiosalicylic Acid, a Novel Therapeutic for Letrozole Insensitivity and Resensitization of previously Hormonal Resistant Breast Cancer Cell"

"Diagnostic Accuracy of Effusion Cytology in Patients with Concomitant Serosal Biopsies."